Fig. 1

Overview of tumor samples and predicted and validated fusion transcripts. A Number of samples that have RNA-Seq data with and without matched WGS data for validation of fusion transcripts. B Detected fusion transcripts per sample and cancer type after removing fusions flagged by FusionCatcher as likely false positives. C Distribution of the number of validated gene fusions per sample and cancer type. D Fraction of the validated fusion genes that had discordant read pairs and at least one determined genomic breakpoint. The three different types of kidney cancer were pooled for plotting